MC

548.4

+0.88%↑

SANES

8.769

+0.11%↑

SAF

305.2

+0.33%↑

BBVA

16.53

+0.43%↑

BNP

77.59

-0.27%↓

MC

548.4

+0.88%↑

SANES

8.769

+0.11%↑

SAF

305.2

+0.33%↑

BBVA

16.53

+0.43%↑

BNP

77.59

-0.27%↓

MC

548.4

+0.88%↑

SANES

8.769

+0.11%↑

SAF

305.2

+0.33%↑

BBVA

16.53

+0.43%↑

BNP

77.59

-0.27%↓

MC

548.4

+0.88%↑

SANES

8.769

+0.11%↑

SAF

305.2

+0.33%↑

BBVA

16.53

+0.43%↑

BNP

77.59

-0.27%↓

MC

548.4

+0.88%↑

SANES

8.769

+0.11%↑

SAF

305.2

+0.33%↑

BBVA

16.53

+0.43%↑

BNP

77.59

-0.27%↓

Search

Ipsen SA.

Open

SectorFinance

115.5 -0.09

Overview

Share price change

24h

Current

Min

114.7

Max

116.1

Key metrics

By Trading Economics

Income

220M

334M

Sales

-2.9M

1.8B

P/E

Sector Avg

21.117

28.015

Dividend yield

1.25

Profit margin

18.354

Employees

5,358

EBITDA

-73M

637M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+12.28% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.25%

3.82%

Market Stats

By TradingEconomics

Market Cap

88M

9.4B

Previous open

115.59

Previous close

115.5

News Sentiment

By Acuity

42%

58%

163 / 530 Finance

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Ipsen SA. Chart

Past performance is not a reliable indicator of future results.

Related News

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Ipsen SA. Forecast

Price Target

By TipRanks

12.28% upside

12 Months Forecast

Average 133.17 EUR  12.28%

High 148 EUR

Low 118 EUR

Based on 6 Wall Street analysts offering 12 month price targets forIpsen SA. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

99.85 / 104Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

163 / 530 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat